Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
466 Leser
Artikel bewerten:
(1)

snapIoT: SnapIoT Appoints Industry Veterans Charlie Mains and Christian Knaus To Their Leadership Team.

SAN DIEGO, CA / ACCESSWIRE / SEPTEMBER 11, 2019 / snapIoT, the fastest-growing "Platform as a Service" (PaaS) provider of mobile-connected self-service solutions for clinical trials, announced today the addition of the Vice President of Client Development, Charlie Mains, and Senior Director of Client Development, Christian Knaus to their leadership team.

Growing numbers of biopharma, contract research organizations (CROs), and research centers are engaging snapIoT's clinical trial platform for eConsent, ePRO/eCOA, patient engagement, telehealth virtual visits, data capture, medical device, consumer sensor connections, reports, and insights.

Mains brings over 20 years of experience in the eClinical sector, supporting innovation in patient-centric, technology-driven clinical trials. Mains previous experience includes Signant Health, CRF Health, Medidata, and PHT. For the last nine years, Mains was the Senior Director of Business Development with CRF Health's Strategic Accounts Group.

"I am excited to join a company that is leading the digital revolution in clinical trials. I look forward to helping our clients accelerate their transformation, and maximize the value of our patented platform," said Charlie Mains, Vice President of Client Development

Over the last four years, Knaus has spearheaded the path toward paperless clinical trials specializing in eCOA, BYOD, and wearables. Knaus previous experience includes ICON Plc, ERT, and CareFusion.

"I know that my experience building an industry-leading eCOA team of Project Managers that spanned the US, UK, and Germany will be instrumental to our growth," said Christian Knaus, Senior Director of Client Development. "Both Charlie Mains and I will work closely with our clients to deliver breakthrough technologies for their clinical trials."

The snapIoT platform is an all-in-one solution that works with their client's current eco-system of technology solutions. For the first time, pharmaceutical executives and clinical operations team members have complete visibility into every aspect of a clinical trial in real-time across their entire portfolio of clinical trials in one easy to use, "drag and drop" enabled platform. The snapIoT platform can be "live" for a client, across multiple clinical trials in weeks versus months with no custom programming. Both Mains, and Knaus will work with their clients to ensure the patient's needs are at the center of every solution.

"We are thrilled to have both Charlie and Christian join our leadership team. Both are top performers in the clinical trial space. I am confident that their combined industry experience and network of resources will impact snapIoT's growth on a global scale." said Isaac Eteminan, CEO of snapIoT. "We have the unique opportunity to advance the next generation of clinical trials to fast-track product development and innovation.

About snapIoT

Based in San Diego, California, with offices in Europe, snapIoT is the fastest-growing "Platform as a Service" provider of mobile-connected self-service platform solutions for clinical trials. snapIoT's senior leadership comes from the chipset division of Qualcomm, where they specialized in Core Embedded IP/LTE Multimedia Systems. They have delivered projects across many patient populations around the globe. Building on this experience, snapIoT has designed and implemented self-service mClinical IoT solutions for CROs and pharmaceutical companies. For more information and to request a free user experience, visit http://www.snapiot.com.

Sales & Press Inquiries:

Mary Briggs
VP Delivery Excellence
mary@snapiot.com

SOURCE: snapIoT



View source version on accesswire.com:
https://www.accesswire.com/559236/SnapIoT-Appoints-Industry-Veterans-Charlie-Mains-and-Christian-Knaus-To-Their-Leadership-Team

© 2019 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.